Helsinn Healthcare S.A. et al. v. Dr. Reddy's Laboratories

Case overview — Helsinn Healthcare S.A. v. Dr. Reddy's Laboratories, No. 2:14-cv-04274 (D.N.J.)

The parties. Both sides are operating pharmaceutical companies, not NPEs or PAEs. Helsinn Healthcare S.A. is a privately held Swiss specialty-pharma company based in Lugano that develops supportive-care products; palonosetron, the active ingredient in its branded antiemetic Aloxi® (palonosetron HCl injection), was acquired for development in 1998, and Aloxi was approved by FDA in 2003 (NDA No. 021372). In the U.S., Aloxi is commercialized by Eisai Inc., which acquired Helsinn's North American marketing partner MGI Pharma in 2008, and Eisai publicly supported Helsinn in the litigation. Co-plaintiff Roche Palo Alto LLC is a Roche research subsidiary and co-assignee of the formulation patents; it is named because it holds title with Helsinn, not because it markets Aloxi. The defendants are Dr. Reddy's Laboratories, Ltd. (Hyderabad, India) and its U.S. subsidiary Dr. Reddy's Laboratories, Inc. (Bridgewater, New Jersey), a generic-drug manufacturer; Teva Pharmaceuticals USA, Inc./Teva Pharmaceutical Industries, Ltd. were co-defendants in the consolidated companion action, No. 14-6341 (SRC). Helsinn's district-court litigation counsel was Porzio Bromberg & Newman (Charles M. Lizza) with Loeb & Loeb (Mark E. Waddell) as of counsel; DRL's IPR papers were handled by Paul Hastings and Finnegan.

Accused products and patents. The case is a Hatch-Waxman action under 35 U.S.C. § 271(e)(2)(A). The accused products are generic palonosetron HCl intravenous solutions at the two Aloxi strengths — 0.25 mg (base)/5 mL and 0.075 mg (base)/1.5 mL, both 0.05 mg/mL — filed under DRL's ANDA No. 201533 and Teva's ANDA No. 090713, with Paragraph IV certifications against the Orange Book–listed palonosetron patents. The patent identified in this case's metadata is U.S. Patent No. 7,947,724 ("Liquid Pharmaceutical Formulations of Palonosetron," issued May 24, 2011, from App. No. 11/186,311, a continuation of PCT/EP2004/000888, claiming priority to provisional 60/444,351 filed January 30, 2003, and co-assigned to Helsinn and Roche Palo Alto). In one line: the '724 patent claims stable, ready-to-use aqueous palonosetron formulations — the asserted claims are composition/method claims built around a 0.05 mg/mL palonosetron HCl concentration, a chelating agent (EDTA), mannitol and a buffer at pH ~5.0, and a method of "reducing emesis" by administering a 0.25 mg dose in a 5 mL solution; its U.S. term ran to July 30, 2024 with pediatric exclusivity (per FDA approval letters for ANDAs 201533, 202521, 090713). One important docket nuance: the complaint filed July 7, 2014 in 14-4274 pleaded the then-newly-issued '094 patent (issued May 20, 2014), and the amended complaint of September 2, 2015 added the '980 patent (issued June 20, 2015); the '724 patent was pleaded and tried in the same D.N.J. palonosetron program — the consolidated 12-2867/14-4274 DRL proceeding in which the court addressed '724 claim 9 alongside '094 and '980 claims. Anyone reading the '724 reference in the case metadata should therefore understand it as the lead patent of the family litigated across these consolidated D.N.J. actions rather than the sole patent named in the 2014 complaint.

Posture, venue, and significance. The case was filed in the District of New Jersey, Newark vicinage (2:14-cv-04274), and assigned to Judge Stanley R. Chesler (the earlier palonosetron actions were handled by Judge Mary L. Cooper in Trenton, 3:11-cv-03962, 3:12-cv-02867, 3:13-cv-05815). Venue made sense: DRL's U.S. subsidiary and agent is in Bridgewater, N.J., D.N.J. is the historically dominant Hatch-Waxman forum and had already absorbed the entire Aloxi ANDA wave (Helsinn sued at least fifteen ANDA sponsors), and consolidation before one court avoided duplicative Markman and invalidity proceedings. The 14-4274/14-6341 track produced two substantive rulings: on January 30, 2018, Judge Chesler denied Helsinn's preliminary injunction to block Teva's at-risk launch (D.I. 89) because Teva had raised a substantial question that claim 4 of the '094 patent was reduced to practice before the January 30, 2002 critical date — chiefly through a 2010 PTO declaration Helsinn itself had submitted — and on December 21, 2018 he issued a claim construction opinion (D.I. 152) holding that "reducing/reduces the likelihood" carries its plain meaning of "decreasing the probability," with prosecution disclaimer in the '724 family barring Helsinn's "preventing" construction. The case is notable for three reasons. First, it is the sibling of the case that produced the Supreme Court's decision in Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., 586 U.S. 282 (Jan. 22, 2019), affirming the Federal Circuit, 855 F.3d 1356 (Fed. Cir. 2017), that a confidential sale to a third party can trigger the AIA on-sale bar; the 14-4274 court's PI analysis was expressly framed against that backdrop while Helsinn's en banc and certiorari petitions were pending. Second, it marks the commercial tipping point: after the PI

I'll research this case across the docket, PTAB, and Federal Circuit records.

I'll research the docket and counsel for this case.

Let me pull the actual docket and complaint to confirm counsel of record.

I'll research the docket and counsel for this specific case number.

Let me pull the actual docket sheets and party/attorney listings.

Let me find the 2018 opinions in 14-4274, which typically list appearances/counsel.

Bottom line

Counsel of record for the Dr. Reddy's entities in this Aloxi®/palonosetron family is best documented as Lite DePalma Greenberg, LLC (Newark, NJ) — Michael E. Patunas and Mayra V. (Velez) Tarantino, who served as Dr. Reddy's New Jersey counsel throughout the consolidated D.N.J. palonosetron litigation. I was not able to retrieve a 14-4274-specific appearance block from a docket sheet in this session (the free docket sources expose only two documents for 2:14-cv-04274 — Dkt. 89 and Dkt. 152 — neither of which attaches a full appearance list). I therefore flag confidence levels below rather than assert an unverified roster.

Counsel identified

Sources: CourtListener RECAP for D.N.J. 3:11-cv-03962, Dkt. 176, at the signature/appearance block — https://storage.courtlistener.com/recap/gov.uscourts.njd.[261662](/patent/261662).176.0.pdf and https://www.courtlistener.com/docket/[4310416/176](https://assignmentcenter.uspto.gov/search/patent/reelFrameDetail?reelFrame=4310416-0176)/1/helsinn-healthcare-sa-v-dr-reddys-laboratories-ltd/ ; Lite DePalma Greenberg appearance block reproduced at https://insight.rpxcorp.com/litigation_documents/[12815904](/patent/12815904) ; counsel listing in the reported Helsinn/DRL opinion at https://case-law.vlex.com/vid/helsinn-healthcare-s-v-893406161.

What I could not verify (and will not invent)

1. No confirmed 14-4274 docket-sheet appearance list. The govinfo/Judicial Conference metadata package for 2:14-cv-04274 (https://www.govinfo.gov/app/details/USCOURTS-njd-2_14-cv-04274) enumerates the following attorney names without pairing them to parties: Zachary B. Cohen, Alison S. Cooney, Elizabeth E. Grden, Andrew C. Nichols, Maria C. Nunez, Young J. Park, Alexander C. Plushanski, Alyssa E. Ramirez, Loren G. Rene, David Y. Wang, Dana R. Weir. I have not attributed any of these to Dr. Reddy's — the metadata does not identify which side they represent, and I found no secondary source tying them to DRL. They should be treated as an open item to resolve against the PACER docket (D.N.J. ECF) rather than as defendant's counsel.
2. National/lead (out-of-state) counsel for DRL in this action is unconfirmed. In the broader Helsinn palonosetron litigation the New Jersey filings I retrieved were signed by Lite DePalma Greenberg for DRL; the coordinated out-of-state firms I saw in the record were Winston & Strawn LLP (Chicago/Washington) and Lite DePalma for Teva, not DRL. I will not assign Winston & Strawn to Dr. Reddy's on that record.
3. No in-house counsel for Dr. Reddy's appears in any retrieved filing.
4. Whether DRL's appearance in 14-4274 was terminated. DRL stipulated to dismissal from the 11-3962 lead case on October 16, 2015 (Dkt. 355 in 11-3962), and per Sagent's 2018 filing DRL settled its Aloxi® case with Helsinn and launched its generic on March 26, 2018 — so any DRL appearance in 14-4274 likely ended in a stipulation of dismissal that I did not retrieve. The two published opinions in 14-4274 (Dkt. 89, Jan. 30, 2018 and Dkt. 152, Dec. 21, 2018) are directed to Teva/claim construction, not to DRL.

Flags on the case metadata (please reconcile before publication)

• Patent-at-issue discrepancy. The metadata lists only U.S. Patent No. 7,947,724. However, Judge Cooper's Feb. 14, 2017 opinion in the companion case states: "Helsinn also brought Civil Case No. 14-4274 in this court asserting infringement of the '094 and '980 patents" (3:12-cv-02867, Dkt. 232, at 3 n.3 — https://cases.justia.com/federal/district-courts/new-jersey/njdce/3:2012cv02867/[274275/232](https://assignmentcenter.uspto.gov/search/patent/reelFrameDetail?reelFrame=274275-0232)/0.pdf). The '724 patent was asserted in 11-3962 and 12-2867, not (on this record) in 14-4274. The reported decisions and commentary on 14-4274 likewise treat the '094 and '980 patents as the patents-in-suit (see Robinson Saplan, noting Nos. 14-4274 (SRC),